Brian Furmanski, PhD

Vice President, Regulatory Affairs

Brian Furmanski is the Vice President of Regulatory Affairs at Kriya Therapeutics. Dr. Furmanski joins Kriya from Nuventra Pharma Sciences where he was the Senior Director of Clinical Pharmacology and Regulatory Affairs. Prior to Nuventra, Dr. Furmanski was a Senior Clinical Pharmacology Reviewer at the FDA where he reviewed and provided regulatory and scientific advice on hundreds of IND, NDA and BLA submissions. Before his time at the FDA, Dr. Furmanski was an investigator in the muscle metabolism and repair group at GlaxoSmithKline. He started his career at Siga Technologies where he contributed to the development of novel antiviral therapies.

Dr. Furmanski received his PhD in biochemistry from the University of South Carolina and completed his postdoctoral fellowship at St. Jude Children’s Research Hospital.  Dr. Furmanski received his undergraduate degrees in economics and engineering, also from the University of South Carolina.